Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
With Hurricane Matthew scheduled to hit the East Coast later this week, Jacksonville, Fla.-based hospitals are readying supplies and reviewing emergency action plans, according to News4jax.
The Food and Drug Administration has approved 17 new drugs in 2016, with several regulatory decisions set to be made in October, according to Zacks Investment Research.
The United States Drug Enforcement Administration reduced the number of almost every opioid medication approved for manufacturing in 2017 by 25 percent or more.
New Brunswick, N.J.-based Johnson & Johnson identified a low-risk security issue in one of its insulin pumps that could allow hackers to overdose diabetic patients with insulin, reported Reuters.
Cambridge, Mass.-based Sarepta Therapeutics recently entered into a licensing and collaboration agreement with Abingdon, U.K.-based Summit Therapeutics.
FedEx and United Parcel Service are already preparing for the expected spike in package deliveries between Thanksgiving and Christmas, according to The Wall Street Journal.
Federal lawmakers are expressing concerns over high prescription drug costs — a problem they may have inadvertently contributed to, according to KRQE News.
A Mylan spokeswoman said the company's generic EpiPen may not be available until the end of 2016, according to Bloomberg.
The Institute for Supply Chain Management's manufacturing index jumped from 49.4 in August to 51.5 in September, according to The Wall Street Journal.
St. Paul, Minn.-based St. Jude Medical earned Food and Drug Administration approval for its BurstDR stimulation technology, a physician-developed form of spinal cord stimulation used to treat patients with chronic pain.